We use analytics and advertising cookies, which you can accept or reject; see our privacy policy.

Current choice:

LAG-3

LAG-3 inhibitors and ligands target lymphocyte activation gene-3 (LAG-3), an inhibitory receptor on T cells. The gene was cloned in 1990 from activated lymphocytes, and its protein is closely related to the coreceptor cluster of differentiation 4 (CD4). Like CD4, LAG-3 binds major histocompatibility complex class II (MHC-II) molecules on antigen-presenting cells. A 2019 study identified fibrinogen-like protein 1 (FGL1), a liver-secreted protein, as a further major inhibitory ligand. LAG-3 is often coexpressed with programmed cell death protein 1 (PD-1) on exhausted T cells. Ieramilimab is an anti-LAG-3 antibody, and SA-15-P is a small molecule reported to block both the LAG-3/MHC-II and LAG-3/FGL1 interactions. LAG-3-IN-2 and LAG-3 degrader 1 extend the small-molecule tools for this checkpoint receptor.

5 Items

  • Ieramilimab — antibody illustration
    Cat. No.
    AT0153
    CAS No.
    2137049-37-5

    Ieramilimab

    Synonyms: LAG525; IMP701

    Ieramilimab (LAG525; IMP701) is a humanized IgG4 monoclonal antibody designed to target and bind to lymphocyte-activation gene 3 (LAG-3). This interaction effectively inhibits the binding of LAG-3 to major histocompatibility complex class II (MHC-II) molecules, which is critical in modulating immune response. Ieramilimab is utilized extensively in research focused on immune checkpoint regulation and potential therapeutic interventions for various immunological disorders.

    In stock View Details
    1 mg
    $228.00
    5 mg
    $574.40
    All 3 sizes
  • Tebotelimab — antibody illustration
    Cat. No.
    AT0198
    CAS No.
    2245725-04-4

    Tebotelimab

    Synonyms: MGD-013

    Tebotelimab (MGD-013) is a humanized IgG4κ bispecific antibody designed for dual affinity re-targeting (DART) of PD-1 and LAG-3. This therapeutic agent demonstrates high affinity binding to cell-surface expressed PD-1 and LAG-3, with half-maximal effective concentrations (EC50s) of 1.65 nM and 0.41 nM in NS0 cells, respectively. By effectively blocking the interactions between PD-1/PD-L1, PD-1/PD-L2, and LAG-3/HLA (MHC-II), as well as inhibiting PD-1 signaling pathways, Tebotelimab plays a crucial role in restoring the function of exhausted T-cells. This restoration is pivotal in enhancing anti-tumor immunity, making Tebotelimab a significant tool in cancer immunotherapy research.

    In stock View Details
    1 mg
    $520.00
    5 mg
    $1,344.00
    All 3 sizes
  • Favezelimab — antibody illustration
    Cat. No.
    AT0866
    CAS No.
    2231068-83-8

    Favezelimab

    Synonyms: MK-4280

    Favezelimab (MK-4280) is a humanized monoclonal antibody targeting LAG-3, designed to inhibit the binding of LAG-3 to MHC class II molecules. This interaction blockade enhances T-cell function and may potentiate an anti-tumor immune response. Favezelimab is primarily investigated for its therapeutic potential in colorectal cancer research, particularly in combination with the PD-L1 inhibitor Pembrolizumab, to synergistically enhance immune-mediated tumor suppression.

    In stock View Details
    1 mg
    $320.00
    5 mg
    $960.00
    All 3 sizes
  • Relatlimab — antibody illustration
    Cat. No.
    AT1107
    CAS No.
    1673516-98-7

    Relatlimab

    Synonyms: BMS-986016

    Relatlimab (BMS-986016) is a human monoclonal antibody targeting LAG-3, developed through the immunization of transgenic mice engineered to express human immunoglobulin miniloci, using recombinant LAG-3 protein. This antibody effectively inhibits the interaction between LAG-3 and MHC II with an IC50 of 0.67 nM, and between LAG-3 and FGL1 with an IC50 of 0.019 nM. It is primarily utilized in cancer research, providing a valuable tool for investigating the role of LAG-3 in tumor immune evasion and potential therapeutic interventions.

    In stock View Details
    1 mg
    $160.00
    5 mg
    $520.00
    All 3 sizes
  • Miptenalimab — antibody illustration
    Cat. No.
    AT1179
    CAS No.
    2249882-55-9

    Miptenalimab

    Synonyms: BI-754111

    Miptenalimab (BI-754111) is a monoclonal antibody targeting human LAG-3 with a dissociation constant (K_D) of 88.6 nM. This antibody effectively inhibits the interaction between LAG-3 and its physiological ligand MHC class II, highlighting its potential utility in modulating immune responses in oncological and immunological research.

    In stock View Details
    1 mg
    $450.00
    5 mg
    $1,400.00
    All 3 sizes

5 Items

Added to your cart

View Cart Checkout

    Loading...